Octreotide LAR and tamoxifen versus tamoxifen in phase III randomize early breast cancer trials: NCIC CTG MA.14 and NSABP B-29

NCIC CTG MA.14 and NSABP B-29 trials examined the addition of Octreotide LAR (OCT) to 5 years of tamoxifen (TAM). Gallbladder toxicity led to B-29 discontinuation of OCT, and MA.14 OCT administration shortened to 2 years. Median follow-up was 9.8 years for 667 MA.14 patients and 6.8 years for 893 B-...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Breast Cancer Res Treat
Autors principals: Chapman, Judith-Anne W., Costantino, Joseph P., Dong, Bin, Margolese, Richard G., Pritchard, Kathleen I., Shepherd, Lois E., Gelmon, Karen A., Wolmark, Norman, Pollak, Michael N.
Format: Artigo
Idioma:Inglês
Publicat: 2015
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4681581/
https://ncbi.nlm.nih.gov/pubmed/26276354
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10549-015-3547-4
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars